Biosimilars in the Evolving Cancer Care Landscape: Experts Address Current Questions, Controversies, and Impact on Clinical Practice

In this online educational program, Jeffrey Crawford, MD, Lee Schwartzberg, MD, FACP, and Andrew D. Zelenetz, MD, PhD, explore the impact of biosimilar oncology drugs on patient care and discuss current questions regarding the use of these agents in clinical practice.

Downloadable Slideset

In this downloadable slideset from the NCCN Biosimilars symposium, Andrew D. Zelenetz, MD, PhD, Jeffrey Crawford, MD, and Lee S. Schwartzberg, MD, FACP, provide expert perspective on integrating biosimilar drugs into your practice to improve the care of patients with cancer.

Released: March 8, 2018
Jointly provided by the National Comprehensive Cancer Network and Clinical Care Options, LLC

Ann Gianola, MA
Manager, Continuing Education Accreditation
National Comprehensive Cancer Network
275 Commerce Drive, Suite 300
Fort Washington, PA 19034

215-690-0239
215-690-0283 (Fax)
gianola@nccn.org
For Clinicians:
NCCN.org
For Patients:
NCCN.org/patients

This activity is supported by educational grants from
Amgen
Pfizer Inc.
Sandoz Inc., a Novartis Division

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?